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ORIGINAL ARTICLE
INTRODUCTION
Complaint related to upper gastrointestinal tract 
(dyspepsia syndrome) is often experienced by diabetic 
patients. The results of previous studies showed that 
the prevalence of dyspepsia in diabetes ranges from 
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ABSTRACT 
 Background: Chronic Helicobacter pylori (H. pylori) infection affects the mechanisms of gastric mucosal 
protection. In patients with diabetes mellitus, data on the prevalence of H. pylori infection are scanty and 
contradictory. We have examined, using histological fixation technique, the thickness of the adherent mucus gel 
layer in the gastric mucosal and H. pylori infection in dyspeptic patients with or without diabetes.
 Method: A cross-sectional study was conducted in 86 dyspeptic patients consisted of 43 diabetics and 
43 non-diabetics patients. In all cases, upper gastrointestinal endoscopy were performed, measurement of the 
gastric corpus and antral mucus thickness was carried out at the corpus and antral biopsy specimens were snap 
frozen and cryostat sections were stained using a hematoxyline eosin. One biopsy within 2 cm of the pylorus 
was examined for detection of H. pylori status by using polymerase chain reaction (PCR).
 Results: In all sections the mucus layer was continuous. At the gastric corpus and antrum, the mucus 
thickness of diabetic patients was thinner (35.2 ± 2.2 µm and 43.9 ± 3.8 µm) than non diabetic patients 
(45.2 ± 2.5 µm and 51.2 ± 2.2 µm). The results were significantly different (p = 0.001). The difference of 
H. pylori prevalence between diabetics (52.5%) and nondiabetics patients (47.5%) was not significant (p = 0.67). 
 Conclusion: This study shows a significant thinning of the adherent mucus gel layer both in diabetic 
patients and H. pylori-positive individuals. No difference has been found between patients with H. pylori infection 
and diabetes mellitus.
 Keywords: mucus thickness, Helicobacter pylori infection, diabetic patient
13-20%.1 Dyspepsia syndrome is often associated 
with delayed gastric emptying (gastro paresis). 
The prevalence of gastroparesis in type I diabetes 
ranges from 27–58%; and it ranges from 30-60% in 
type 2 diabetes.2,3 The main cause of complex diabetic 
gastroparesis is autonomic neuropathy, others are 
genetic factor, inflammation, and fibrosis in gastric 
smooth muscles.3 Consequently, gastroparesis may 
increase the risk of Helicobacter pylori (H. pylori) 
infection and defensive factors disturbance.4-9 It has 
been estimated that defensive factors in diabetes 
mellitus have been disturbed causing increased  risk of 
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aberration in gastric and duodenal mucosa.10,11 Suzuki 
et al reported that their study in diabetic rats showed 
disturbance on the gastric mucosal defensive factors.12
The defensive factors are originated in mucosa 
microcirculation, which in normal condition they 
have a role to maintain mucus, bicarbonate secretion, 
and epithel restitution process. The microcirculation 
is affected by blood pressure, vasoconstrictors, such 
as thromboxane A2, adrenalin and noradrenalin, also 
by vasodilators, such as prostaglandin type E2 (PGE2) 
and nitric oxide (NO2) that secreted by capillary 
endothel.9,13,14 One of chronic complications in diabetes 
is microangiopathy that will cause gastric mucosal 
blood flow disturbance. A study conducted by Suzuki 
in diabetic rats showed that there was a reduction in 
gastric mucosal blood flow.12 A study by Shengyuan et 
al utilizing the laser Doppler flowmeter on 14 points of 
gastric mucosa in diabetic patients showed a significant 
reduction on gastric mucosal blood flow compared 
with control.15 There was a correlation between mucus 
thickness and intragastric acid production in order 
to maintain the gastric balance.9 Hassler et al who 
studied the intragastric pH testing in diabetic patients, 
found that intragastric pH in diabetic patients was 
higher than non-diabetics.11 Allen et al reported that 
minimal mucus thickness in human was 50 µm. While 
Phillipson et al reported that minimal mucus thickness 
in rats in vivo was 80 µm, which act as a protection 
from gastric acid, pepsin, drugs, and irritants that may 
damage gastric mucosal layer.16,17,18 So far, studies 
about mucus thickness in diabetic patients have never 
been performed. 
The correlation between H. pylori infection and 
dyspepsia in diabetic patients are still controversial.1,5,8 
Papamichael et al summarized several studies in 
type 1 and type 2 diabetes mellitus.8 Controversial 
findings had been reported, especially about H. pylori 
infection and duration of illness, blood fasting glucose, 
age, sex, body mass index (BMI), the severity of 
dyspepsia complaint, hypertension, and cardiovascular 
neuropathy. Such findings may be caused due to 
different identification methods for H. pylori.  
METHOD
The present study was a cross-sectional study 
design which was performed in 2 groups of study 
samples. The first group was 43 diabetic patients 
with dyspepsia complaints and the second group 
was 43 non-diabetic dyspeptic patients. All patients 
underwent upper gastrointestinal endoscopy to look 
for the abnormalities/lesion and they also had gastric 
mucosa biopsy. 
The sampling was performed consecutively at 
the outpatient clinic and endoscopic procedure room at 
the hospitals: Cipto Mangunkusumo, Pantiwilasa, and 
Gatot Soebroto between April 2010 and June 2010. The 
inclusion criteria in this study were: (1) Patients 18 – 60 
years of age; (2) Dyspeptic patients with or without 
diabetes. The exclusion criteria were: (1) Patients with 
acute or chronic liver disease; (2) Patients with chronic 
kidney disease; (3) Patients with gall stone; (4) Patients 
with history of abdominal/upper gastric surgery; (5) 
Patients with heart failure who were at New York Heart 
Association (NYHA) class III or IV; (6) Patients with 
history of stroke; (7) Patients who took aspirin and 
non-steroidal anti-inflammation drugs; (8) Patients or 
patients’ family who refused to undergo endoscopy; 
(9) Patients who had other gastric mucosa abnormality 
during the endoscopic examination, for example 
patients who have been suspected for malignancy; (10) 
Uncooperative patients. 
Of the H. pylori DNA testing in biopsy specimens, 
86 samples from the gastric antrum of dyspeptic 
patients were analyzed by po lymerase chain reaction 
(PCR) procedure to detect the presence of H. pylori 
by using urease C/ureC gene (glmM, 294 bp). 
For the gastric mucosal mucus examination, the biopsy 
specimen should be confirmed that it was adequately 
large and intact to be adhered with the embedding 
medium for frozen preparation (Cryo matric) and 
be frozen. The tissues were cut at 12 µ by cryo cut 
microtome set at -20oC, and then it was fixated and 
stained with hematoxylin eosin stain. The preparation 
was analyzed under the light microscope to identify the 
thickness of gastric mucosal mucus as being measured 
by ocular micrometer scale under magnification of 
40 x 10.
In order to differentiate the mean of mucus 
thickness in dyspeptic patients who also had type 
2 diabetes mellitus and the non-diabetic patients, 
2 mean difference for independent t-test was used. 
For categorical data, the non-parametric test, 
Chi-square was used and when the data has fulfilled 
the requirements, the Fisher and Kolmogorov Smirnov 
tests were utilized. Afterward, the data was analyzed 
by using SPSS 15 for Windows. Study protocol had 
been submitted to and approved by Ethical Committee 
at Faculty of Medicine, University of Indonesia. 
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RESULTS
Table 1. Characteristic of dyspepsia patients with and without diabetes
Variable
Dyspepsia
p
Diabetic Non diabetic
Number of subject 43 43
Sex
       Male 22 21
        Female 21 22
Age (year) 49.2 ± 7.6 46.5 ± 9,6 0.158
Fasting blood glucose (mg/dL) 162 ± 29.64 91.97 ± 7,03
Postprandial blood glucose (mg/dL) 241.51 ± 39.73 121.72 ± 13.66
HbA1C 6.9 ± 0.7
Body mass index 24.2 ± 1.0 23.9 ± 1.1 0.333
Duration of diabetes (year) 5.2 ± 3.8
Antrum
       Hyperemic 43 (51.8) 28 (48.2)
       Erosive 30 (69.8) 12 (30.2)
       Ulcus 10 (76.9) 3 (23.1)
Corpus
        Hyperemic 40 (57.1) 30 (42.9)
        Erosive 12 (54.8) 9 (45.2)
        Ulcus 0 0
Mucus thickness     
        Antrum 35.9 ± 2.2 44.1 ± 3.8 < 0.001
        Corpus 45.2 ± 2.5 51.0 ± 2.7 < 0.001
Helicobacter pylori infection
          Positive polymerase chain reaction 21 (52.5%) 19 (47.5%) < 0.001
        Positive histopathology 2 (50%)        2 (50%) < 0.001
Table 2.  The gastric mucosal mucus thickness in dyspepsia patients with Helicobacter pylori infection
Mucus thickness
Dyspepsia (n = 86)
p
Positive H. pylori Negative H. pylori
Antrum (µm) 38.0 ± 4.3 41.8 ± 5.2 < 0.001
Corpus (µm) 46.7 ± 3.3 49.3 ± 3.9 < 0.001
Table 3.  The gastric mucosal mucus thickness in diabetic patients with Helicobacter pylori infection
Mucus thickness
Dyspepsia with diabetic (n = 43)
p
Positive H. pylori Negative H. pylori
Antrum (µm) 34.6 ± 1.7 37.1 ± 2.0 < 0.001
Corpus (µm) 42.7 ± 2.6 48.9 ± 2.3 < 0.001
Table 4. The gastric mucosal mucus thickness in non-diabetic patients with Helicobacter pylori infection
Mucus thickness
Dyspepsia non-diabetic (n = 43)
p
Positive H. pylori Negative H. pylori
Antrum (µm) 41.7 ± 3.2 46.0 ± 3.2 < 0.001
Corpus (µm) 49.0 ± 2.5 52.6 ± 1.7 < 0.001
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DISCUSSION 
The study about gastric mucosal mucus thickness 
was previously reported in animals. After Jordan et al 
had found a method visualizing mucus layer in human, 
then studies on mucus thickness had been started.19 
Atuma et al evaluated mucus thickness of rats in vivo 
under anesthesia by using micropipette for gastric 
acid sampling. Such technique was considered to be 
more representatives to evaluate the overall gastric 
mucus thickness.20 Theoretically, the mucus layer is an 
initial barrier for upper gastrointestinal tract from any 
substance entering the intestinal lumen. It protects cells 
from the digestive process or chemical contacts.21, 22, 23  
In the present study, the antral gastric mucosal 
mucus thickness in diabetic patients was 35.9 ± 
2.2 µm; while in non-diabetic patients was 45.9 ± 
3.9 µm. Statistically, such difference was significant 
(p = 0.000). Moreover, the mucus thickness of gastric 
corpus in diabetic patients was 45.2 ± 2.5 µm and 
51.2 ± 2.2 µm in non-diabetics. It was statistically 
showed significant difference (p = 0.000). Antono 
found that the mucus thickness of NSAIDs users was 
37.4 ± 9.2 µm at the antrum area and 43.3 ± 
Table 5. Histopathological gastropathy in diabetic and non-diabetic patients
Gastropathy–histopathology
Dyspepsia (n = 86)
p
Diabetic (%) Non diabetic (%)
Polymorphonuclear cell 
      Mild 1 (20.0) 4 (80.0)
      Moderate-severe 1 (50.0) 1 (50.0)
Mononuclear cell
      Mild 10 (26.3) 28 (73.7) < 0.001
      Moderate-severe 31 (75.6) 10 (24.4) < 0.001
Gland atrophy
      No atrophy 20 (47.6) 22 (52.4) 1.0
      Mild 20 (52.6) 18 (47.4) 1.0
      Moderate-severe 3 (50.0) 3 (50.0)
Figure 1. Boxplot of the antral gastric mucosal mucus thickness in 
diabetic and non-diabetic patients
Figure 2. Boxplot the corpus gastric mucosal mucus thickness in 
diabetic and non-diabetic patients
Figure 3. Antral mucus with hematoxylin eosin staining
Std : standard
C-   : negative control 
C+ : positive control
S1 : subject 1
S2 : subject 2
Figure 4. Specific band of Helicobacter pylori based on PCR method 
using ureC/glmM primer
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three-fold in soluble mucus/loosely adherent mucus 
(the dynamic and mobile mucus, a lubricating layer).28 
It has been proven that prostaglandin E1 analog may 
significantly decrease gastroscopic lesion compared 
to cimetidine and sucralfate. A study by Taye et al 
reported that in diabetic rats using pyoglitazone the 
mucus thickness also increased.29 Similar results were 
also reported by Iijima et al by using the technique of 
endoscopy gastrin test. They showed that rebamipide 
may also increase mucus thickness.30 We believe that 
the more thickness in gastric mucosal mucus, the easier 
to prevent gastric epithel cells damage. In addition to 
gastric mucosal mucus thickness, the quality of mucus 
glycoprotein components (serine, threonine, proline, 
and oligosaccharides chains) may also have role to 
maintain its integrity.9 Moreover, a lot of other factors 
that may have role, such as prostaglandin, secretin, 
gastrin and cholecytokinine that stimulate the mucus 
secretion.9 Those factors have not been investigated 
yet regarding its correlation or effects on the mucus 
thickness and the study may be difficult. Therefore, 
whether thicker mucus will be comparable with the 
quality of gastric mucosa is still unknown. Based on 
the data, we believe that the gastric mucosal mucus 
layer thickness was a reflection or final result of an 
overall pre-epithelial protection function. 
In the present study, there were 86 biopsy samples 
collected from dyspeptic patients aged 28–60 years, 
all the patients experienced gastritis as determined by 
pathological anatomy test. This study also detected 
H. pylori in gastric biopsy of the patients through 
PCR technique using ureC primary gene/glmM that 
has closely correlated to colonization and bacteria 
pathogenation activity in gastrointestinal tract. Of 
the 86 tested biopsy samples, 4 (5.4%) samples showed 
positive result by histopathological examination; 
while by ureC/glmM PCR methods, 38 (46.3%) 
patients showed positive results. Zsikla et al reported 
that PCR methods may increase the detection rate of 
H. pylori about 20% compared to the histopathological 
examination.31
H. pylori may enter human body during childhood 
and may survive until adulthood. Moreover, it is not 
easy to be cultured or need a very specific condition 
for culture. Therefore, one of the techniques performed 
for fast detection is the specific PCR test since it can 
trace a very specific H. pylori genes and very sensitive 
as it can double its DNA to million times, even when 
originated only from 1 or 2 bacteria.32 In this study, 
detection of H. pylori was based on deoxyribonucleate 
acid which have potency to be utilized for diagnosis by 
using markers that was a general marker for bacteria 
structure and pathogenesis factors such as species 
specific ureC/glmM genes.31,32 The facts that PCR 
may quantitatively yield product and genotype with 
13.1 µm at the corpus.24  Atuma et al, who performed 
in vivo technique in rats, reported that the mucus 
layer thickness at antrum was 154 ± 16 µm and at 
corpus was 80 ± 5 µm.20 Various constraints or causes 
may become the reason for those differences, such as 
fixation process with organic materials and embedded 
paraffin causing gel dehydration leading to mucus 
shrinkage or thinner adherent mucus.20  
Most gastroscopic lesions in diabetic patients, 
about 100%, were found at hyperemic antrum; while 
93% lesions were found at the corpus. In non-diabetic 
patients, most lesions were also found at the antrum; 
with 93% hyperemic, and at the corpus 69.7%. 
Anastasios et al also found that gastroscopic lesions 
were located mostly at the antrum.25 One of the reasons 
was because anatomically antrum is in the lowest part.25 
Foods and drugs that taken will directly move down 
to antrum and stop for a while, before entering into 
duodenum. Other reason may be because of the longest 
contact duration of drugs and foods to the gastric mucus 
are at the antrum. Longer duration will increase topical 
irritation, and cause more mucosal damage.26  
The mucus thickness at the antrum tended to be 
thinner compared to the other parts, in accordance 
with the visible gastroscopic images. Such finding is 
consistent with the histological theory about gastric 
mucosal at the corpus, where the epithelial cells are 
thicker and more mucus cells found there compared 
with the antrum.9 Theoretically, in my opinion, the 
mucus layer at the corpus was thicker than antrum 
(table 1). So, it can be said that mucus protection at 
the corpus was better than the antrum and this also 
explained why the most gastroscopic lesions were 
found at the antrum. 
A study by Allen et al reported that the minimal 
mucus thickness in human was 50 µm; while Phillipson 
et al reported that study in rats demonstrated that the 
minimal gastric mucosal mucus thickness was 80 µm 
as a protection against gastric acid, pepsin, drugs and 
irritant agents that can damage the gastric mucosal 
mucus layer.16,17 The results of Fixa et al study reported 
that the mucus thickness may also be affected by sub-
mucosal inflammation process. Our study found that 
there was more histopathologic gastropathy in diabetic 
patients, either moderate or severe mononuclear 
inflammation, compared to the non-diabetic patients and 
statistically, the difference was significant (table 5).27 
The gastric mucosal mucus layer thickness may 
act as protetction against irritant substances, including 
NSAIDs, which had been proven by in vitro study of 
prostaglandin E1 analog effect (misoprostol) on the 
protection of gastric mucosa in rats. In the study, the 
mucus thickness was increased two-fold in insoluble 
gel/firmly adherent mucus layer (the mucus layer 
that firmly attached with the mucosa) and increased 
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sensitivity and specificity nearly 100% compared 
to the conventional methods. However, sometimes 
due to something or another, such sensitivity was not 
obtained or the concentration of DNA product was 
very low.32,33,34   
In the present study, 21 (52.5%) dyspeptic patients 
with diabetes and 19 (47.5%) dyspeptic patients without 
diabetes showed positive results of the H. pylori 
presence on specific band; however, the difference 
was not statistically significant (p = 0.67). Also, 
H. pylori were detected in 1 sample histopathologically 
despite its negative result on PCR. Various constraints 
or causes may be the reasons, such as: (1) Biopsy 
sampling that was only performed once and may be 
less precise site where H. pylori were suspected.5 
It could be managed or at least be minimized by biopsy 
in more than 2 sites, the antrum and corpus; however, 
such action might endanger the patients because it 
could injure their gastric wall; (2) Biopsy contained 
only a very little or some H. pylori bacteria, then 
it disappeared during a quite long DNA extraction 
process where the DNA concentration became lower 
because it was diluted by tissue DNA leading to 
a concentration below the detection threshold.34 
It can be managed by performing nested PCR with inner 
primer and DNA resulting from the first amplification 
product as a template which has sensitivity nearly 
100 times.33,34 Another way is using reverse transcriptase 
PCR (RT-PCR) which had already been performed 
by some researchers;32 (3) The condition of PCR 
amplification such as less specific primer, which means 
that H. pylori bacteria did not contain analyzed genes 
or was not expressing the related genes. Utilization of 
more primers may help to overcome this.32,33,34 The 16S 
RNA gene was proposed as the most suitable gene to 
be used in PCR testing because its number of template 
molecules are most commonly found in H. pylori;33 (4) 
Bacteria may contain target genes, but the annealing 
temperature of PCR was less fit to produce the desired 
DNA. It should be considered that many factors may 
affect the success of PCR, including the possibility of 
contaminated DNA; (5) DNA might be amplified by 
PCR, but sometimes problems arose in electrophoresis 
and visualization that actually caused the loss of or 
undetectable DNA bands. Other sampling such as 
feces can also be used for supporting or completing 
the PCR test results.34  
The prevalence study of H. pylori infection showed 
variation among countries and ranged between 25–80% 
in developing countries.18,35 The study demonstrated that 
the prevalence of H. pylori in dyspeptic patients was 
46.3%; while in dyspeptic patients with diabetes was 
52.5% and without diabetes was 47.5%. The existing 
data about the correlation between H. pylori infection 
and diabetes is still controversial.8 Some studies 
showed higher prevalence of H. pylori in diabetic 
patients compared to non-diabetic.36,37,38,39,40,41,42  It was 
also higher in diabetic patients with micro complication 
and macroangiopathy.40-44 Other studies showed that 
there was no difference regarding prevalence between 
diabetic and non-diabetic patients, i.e. 37.3% vs. 
35.2%; 50.8% vs. 56.4%, 28.1% vs. 29.25%, 33% vs. 
32%.44,45,46,47 Dore et al stated that the absence of such 
difference may be due to infection that occur before 
manifestation of diabetes, i.e. during the childhood.48
In Indonesia, the prevalence of H. pylori was 10.2% 
and 2.9% in dyspeptic patients, respectively as it has 
been reported by Syam et al by histopathological 
method and rapid urease test (RUT) pronto dry,49 and 
Saragih et al by histopathological method.50 Moreover, 
Tokudome et al reported that in region with low 
prevalence of gastric cancer, the used of serology 
method and urea breat test (UBT) produced the results 
of 5% and 3%.51 Such prevalence is different from the 
collaboration study conducted by Murdani et al, which 
used histopathological methods, cultures, and RUT 
with  a result of 68% in Indonesia;52  while the result 
in Japan was 59.5%, a quite similar result compared 
to our study using the PCR methods.52  
The correlation between H. pylori infection and 
diabetic complication is still a debate and need 
further study. Demir et al reported that neuropathy 
complication was often found in diabetic patient with 
H. pylori infection.4 A study by Gucelik et al showed 
that there was a correlation between the virulence of 
H. pylori (CagA) and macroangiopathy complication.39 
Similar results were also reported by Quadri et al and 
Gasbarrini et al in cerebral thrombosis.53,54 Benner et al 
reported that more H. pylori infection was commonly 
found in diabetic patients with obesity.55 
Several studies also showed that the effectiveness 
of H. pylori eradication in diabetic patients is lower 
compared to the non-diabetic patients; therefore, 
they needed a longer time for antibiotics treatment.46 
Likewise, the reinfection rate in a year is higher in 
diabetic patients compared with non-diabetics.56,57,58 
This may be caused by micro vascular changes in the 
stomach of diabetic patients leading to the reduced 
antibiotics absorption or may be caused by the frequent 
use of antibiotics thus possibly develop antibiotics 
resistance against H. pylori strain.52,53 The development 
of H. pylori vaccine may provide hope of effective 
treatment for diabetic patients.56,57 
The mucus thickness in dyspeptic patients who 
had been infected by H. pylori with antrum 38.0 ± 
4.3 µm; corpus 46.7 ± 3.3 µm, was thinner than non-
infected patients with antrum 41.8 ± 5.2 µm; corpus: 
49.3 ± 3.9 µm. Such difference was statistically significant 
(p = 0.001). Similar results were also found in 
diabetic patients with antrum 34.6 ± 1.7 µm; corpus 
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42.7 ± 2.6 µm vs. antrum 37.1 ± 2.0 µm; corpus: 
48.4 ± 2.3 µm. The difference  was also statistically 
significant.  A study by Newton et al reported that there 
was thinning in the mucus layer of H. pylori-infected 
patients.58 Beil et al reported that the thinning was 
caused by H. pylori cytotoxic process in ribosome 
stage from mucus-producing cells.59 Furthermore, Celli 
et al reported that there was rheological changes of 
mucus due to increased pH by urease activities so that 
the mucus layer became thinner.60 Hassler et al reported 
that the increase of intragastric pH was caused by 
H. pylori infection which induced glands atrophy; while 
in our study, most glands atrophy was mild atrophy 
and statistically there was no significant differences 
between diabetic and non-diabetics patients.11
The limitations of our study were: (1) The evaluation 
of mucus thickness was conducted in situ; (2) Detection 
of H. pylori was performed by biopsy at the antrum and 
using the PCR methods. At this moment, the golden 
standard for detecting the presence of H. pylori was by 
culture or by using two evaluation methods which have 
high sensitivity and specificity; (3) The measurement of 
blood glucose level in non-diabetic dyspeptic patients 
was based on the fasting blood glucose and 2-hours 
postprandial blood glucose; it should be better by 
the oral glucose tolerance test (OGTT). 
In this study, there were 4 non-diabetic subjects 
according to the measurement only by random blood 
glucose level and the fasting blood glucose and 2-hours 
postprandial blood glucose testing were not performed, 
but they were still included in the non-diabetic 
group. However, statistically it showed no significant 
difference since the percentage was less than 10% of all 
non-diabetic dyspeptic subjects. Moreover,  the mean 
value of random blood glucose in those subjects were 
still in confidence interval of fasting blood glucose 
level and 2-hours postprandial glucose level; therefore, 
the 4 subjects were probably had normal blood glucose 
level indeed. 
CONCLUSION
The gastric mucus thickness in diabetic patients 
is thinner than non-diabetics. The prevalence of 
H. pylori infection in diabetic patients shows no 
difference with non-diabetics. In addition, the mucus 
thickness is thinner in diabetic dyspeptic patients 
with H. pylori infection compared to patients without 
H. pylori infection. 
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